Soltis Investment Advisors LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 26 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Soltis Investment Advisors LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2021$9,0000.0%10,0000.0%0.00%0.0%
Q3 2021$9,0000.0%10,0000.0%0.00%0.0%
Q2 2021$9,000
+12.5%
10,0000.0%0.00%0.0%
Q1 2021$8,00010,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders